CORT insider trading
HealthcareCORCEPT THERAPEUTICS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CORCEPT THERAPEUTICS INC
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Company website: www.corcept.com
CORT insider activity at a glance
FilingIQ has scored 1,119 insider transactions for CORT since Jan 15, 2015. The most recent filing in our index is dated May 5, 2026.
Across the full history, 34 open-market purchases
and 353 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CORT insider trades is 59.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CORT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding CORT
Frequently asked
- How many insider trades does FilingIQ track for CORT?
- FilingIQ tracks 1,119 Form 4 insider transactions for CORT (CORCEPT THERAPEUTICS INC), covering filings from Jan 15, 2015 onwards. 51 of those were filed in the last 90 days.
- Are CORT insiders net buyers or net sellers?
- Across the full Form 4 history for CORT, 34 transactions (3%) were open-market purchases and 353 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CORT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CORT in?
- CORCEPT THERAPEUTICS INC (CORT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.18B.
Methodology & sources
Every CORT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.